CG Oncology said its PIVOT-006 trial of investigational cretostimogene reduced recurrence risk by 68% versus the control arm in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer measuring 3 cm or less after complete tumor resection. The 367-patient study ran at about 90 sites in the United States and Canada. The company plans to submit a biologics license application in the second quarter of 2027 and present topline results on Dec. 2 at the Society of Urologic Oncology Annual Meeting. The hazard ratio was 0.32 (95% CI: 0.23, 0.45; p<0.0001).
Lexeo Therapeutics reported interim Phase I/II results for investigational gene therapy LX2020 in PKP2 arrhythmogenic cardiomyopathy. High-dose cohorts showed mean reductions of 80% in non-sustained ventricular tachycardia and 44% in premature ventricular contractions at the latest assessment. Ten participants had been dosed; nine had at least 12 months of follow-up by the Oct. 15, 2026, data cutoff. Lexeo said the FDA was open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint for potential accelerated approval.
Summit Therapeutics said the FDA issued a complete response letter for its application for ivonescimab plus platinum-based chemotherapy in previously treated EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer. The agency found substantial evidence of effectiveness had not been established without a statistically significant overall-survival improvement, according to Summit. In the Phase III HARMONi trial, the combination significantly improved progression-free survival (hazard ratio 0.52), while overall survival showed a positive but not statistically significant trend. Summit shares fell 16.5%, the Associated Press reported.

Comments (0)
No comments yet. Be the first!